Welcome! Click here to login or here to register.
DNA damage
Draw a picture

Bujnicki Lab Homepage


Protein FULL name:

cellular tumor antigen p53 isoform a [Homo sapiens].

TP53 (Homo sapiens) is product of expression of TP53 gene.

Human diseases related to this protein:

TP53 is involved in:

DDS in Homo sapiens


FUNCTION: Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over.

COFACTOR: Binds 1 zinc ion per subunit.

SUBUNIT: Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as a homotetramer. Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. In vitro, the interaction of TP53 with cancer- associated/HPV (E6) viral proteins leads to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and P53DINP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Directly interacts with FBXO42; leading to ubiquination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A.

INTERACTION: P03070:- (xeno); NbExp=4; IntAct=EBI-366083, EBI-617698; Q13535:ATR; NbExp=1; IntAct=EBI-366083, EBI-968983; Q99728:BARD1; NbExp=1; IntAct=EBI-366083, EBI-473181; O70445:Bard1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-1790207; Q07817-1:BCL2L1; NbExp=2; IntAct=EBI-366083, EBI-287195; P51813:BMX; NbExp=1; IntAct=EBI-366083, EBI-696657; Q9BX70:BTBD2; NbExp=1; IntAct=EBI-366083, EBI-710091; Q8TDN4:CABLES1; NbExp=1; IntAct=EBI-366083, EBI-604615; Q9ESJ1:Cables1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-604411; P17676:CEBPB; NbExp=3; IntAct=EBI-366083, EBI-969696; Q92793:CREBBP; NbExp=3; IntAct=EBI-366083, EBI-81215; P45481:Crebbp (xeno); NbExp=2; IntAct=EBI-366083, EBI-296306; P55060:CSE1L; NbExp=4; IntAct=EBI-366083, EBI-286709; Q14999:CUL7; NbExp=1; IntAct=EBI-366083, EBI-308606; Q8IWT3:CUL9; NbExp=1; IntAct=EBI-366083, EBI-311123; Q9UER7:DAXX; NbExp=3; IntAct=EBI-366083, EBI-77321; Q09472:EP300; NbExp=3; IntAct=EBI-366083, EBI-447295; Q86XK2:FBXO11; NbExp=3; IntAct=EBI-366083, EBI-1047804; Q9BVP2:GNL3; NbExp=1; IntAct=EBI-366083, EBI-641642; Q13547:HDAC1; NbExp=1; IntAct=EBI-366083, EBI-301834; Q86Z02:HIPK1; NbExp=1; IntAct=EBI-366083, EBI-692891; P09429:HMGB1; NbExp=1; IntAct=EBI-366083, EBI-389432; Q9BUJ2:HNRNPUL1; NbExp=6; IntAct=EBI-366083, EBI-1018153; P42858:HTT; NbExp=2; IntAct=EBI-366083, EBI-466029; Q7Z6Z7:HUWE1; NbExp=2; IntAct=EBI-366083, EBI-625934; Q8N9B5:JMY; NbExp=1; IntAct=EBI-366083, EBI-866435; Q92993:KAT5; NbExp=1; IntAct=EBI-366083, EBI-399080; Q15759:MAPK11; NbExp=1; IntAct=EBI-366083, EBI-298304; Q15759-2:MAPK11; NbExp=1; IntAct=EBI-366083, EBI-303766; Q8IW41:MAPKAPK5; NbExp=1; IntAct=EBI-366083, EBI-1201460; Q00987:MDM2; NbExp=8; IntAct=EBI-366083, EBI-389668; P56273:mdm2 (xeno); NbExp=1; IntAct=EBI-366083, EBI-541233; O15151:MDM4; NbExp=2; IntAct=EBI-366083, EBI-398437; P23511:NFYA; NbExp=2; IntAct=EBI-366083, EBI-389739; P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579; P06748-1:NPM1; NbExp=1; IntAct=EBI-366083, EBI-354150; P09874:PARP1; NbExp=1; IntAct=EBI-366083, EBI-355676; Q96KB5:PBK; NbExp=2; IntAct=EBI-366083, EBI-536853; O75925:PIAS1; NbExp=1; IntAct=EBI-366083, EBI-629434; Q8N2W9:PIAS4; NbExp=1; IntAct=EBI-366083, EBI-473160; P29590:PML; NbExp=1; IntAct=EBI-366083, EBI-295890; P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289; Q05397:PTK2; NbExp=6; IntAct=EBI-366083, EBI-702142; Q06609:RAD51; NbExp=1; IntAct=EBI-366083, EBI-297202; P27694:RPA1; NbExp=1; IntAct=EBI-366083, EBI-621389; P62988:RPS27A; NbExp=1; IntAct=EBI-366083, EBI-413034; P62991:Rps27a (xeno); NbExp=1; IntAct=EBI-366083, EBI-413074; Q8WTS6:SETD7; NbExp=3; IntAct=EBI-366083, EBI-1268586; Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218; P20226:TBP; NbExp=1; IntAct=EBI-366083, EBI-355371; Q13625:TP53BP2; NbExp=1; IntAct=EBI-366083, EBI-77642; Q9H3D4:TP63; NbExp=1; IntAct=EBI-366083, EBI-2337775; O88898:Tp63 (xeno); NbExp=1; IntAct=EBI-366083, EBI-2338025; Q05086:UBE3A; NbExp=1; IntAct=EBI-366083, EBI-954357; Q93009:USP7; NbExp=4; IntAct=EBI-366083, EBI-302474; P11473:VDR; NbExp=2; IntAct=EBI-366083, EBI-286357; Q14191:WRN; NbExp=2; IntAct=EBI-366083, EBI-368417; P12956:XRCC6; NbExp=1; IntAct=EBI-366083, EBI-353208; Q96PM9:ZNF385A; NbExp=1; IntAct=EBI-366083, EBI-1539778; Q9PST7:znf585b (xeno); NbExp=2; IntAct=EBI-366083, EBI-1782562;

SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Endoplasmic reticulum. Note=Interaction with BANP promotes nuclear localization.

DOMAIN: The nuclear export signal acts as a transcriptional repression domain.

PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.

PTM: Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1, which may prevent the interaction with MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.

PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.

PTM: May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.

PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to stabilize it.

PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys- 370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370.

PTM: Sumoylated by SUMO1.

PTM: Demethylation of di-methylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.

DISEASE: Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.

DISEASE: Defects in TP53 are involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239]. ESis a tumor of the esophagus.

DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.

DISEASE: Defects in TP53 may be associated with nasopharyngeal carcinoma [MIM:161550]; also known as nasopharyngeal cancer.

DISEASE: Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.

DISEASE: Defects in TP53 are a cause of lung cancer [MIM:211980].

DISEASE: Defects in TP53 are a cause of choroid plexus papilloma [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.

DISEASE: Defects in TP53 are a cause of one form of hereditary adrenocortical carcinoma (ADCC) [MIM:202300]. ADis a rare childhood tumor, representing about 0.4% of childhood tumors, with a high incidence of associated tumors. ADoccurs with increased frequency in patients with the Beckwith-Wiedemann syndrome [MIM:130650] and is a component tumor in Li-Fraumeni syndrome [MIM:151623].

SIMILARITY: Belongs to the p53 family.

WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and germline TP53 mutations in human cancers; [LINK]

WEB RESOURCE: Name=p53 web site at the Institut Curie; [LINK]

WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; [LINK]

WEB RESOURCE: Name=GeneReviews; [LINK]


WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and polymorphism database; [LINK]

WEB RESOURCE: Name=Wikipedia; Note=P53 entry; [LINK]

NCBI GenPept GI number(s): 120407068
Species: Homo sapiens

Links to other databases:

Database ID Link
Uniprot P04637 P04637
PFAM: - P04637 (Link - using uniprot id)
InterPro: - P04637 (Link - using uniprot id)
CATH: None  
SCOP: None  
PDB: - -

Protein sequence:

TP53 (Homo sapiens) is able to recognize following damages:
TP53 (Homo sapiens) belongs to following protein families:

Title Authors Journal
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S EMBO J Dec. 20, 1984
Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M EMBO J May 1, 1985
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Harlow E, Williamson NM, Ralston R, Helfman DM, Adams TE Mol Cell Biol July 1, 1985
Characterization of the human p53 gene. Lamb P, Crawford L Mol Cell Biol May 1, 1986
Molecular basis for heterogeneity of the human p53 protein. Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V Mol Cell Biol Dec. 1, 1986
A variation in the structure of the protein-coding region of the human p53 gene. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP Gene Oct. 1, 1988
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH Nature Jan. 1, 1990
The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Addison C, Jenkins JR, Sturzbecher HW Oncogene March 1, 1990
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D Proc Natl Acad Sci U S A June 1, 1990
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Bartek J, Iggo R, Gannon J, Lane DP Oncogene June 1, 1990
p53 mutations in colorectal cancer. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP Proc Natl Acad Sci U S A Oct. 1, 1990
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. Science Nov. 1, 1990
Frequent mutation of the p53 gene in human esophageal cancer. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC Proc Natl Acad Sci U S A Dec. 1, 1990
Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G Hum Genet Jan. 1, 1991
The tumor suppressor p53 is bound to RNA by a stable covalent linkage. Samad A, Carroll RB Mol Cell Biol March 1, 1991
Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen. Scheidtmann KH, Mumby MC, Rundell K, Walter G Mol Cell Biol April 1, 1991
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC Nature April 4, 1991
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Bressac B, Kew M, Wands J, Ozturk M Nature April 4, 1991
Mutations of the P53 gene, including an intronic point mutation, in colorectal tumors. Ishioka C, Sato T, Gamoh M, Suzuki T, Shibata H, Kanamaru R, Wakui A, Yamazaki T Biochem Biophys Res Commun June 28, 1991
p53 mutations in human cancers. Hollstein M, Sidransky D, Vogelstein B, Harris CC Science July 5, 1991
p53 gene mutations in Barrett's epithelium and esophageal cancer. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA Cancer Res Aug. 15, 1991
p53 is frequently mutated in Burkitt's lymphoma cell lines. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T EMBO J Oct. 1, 1991
A germ line mutation in exon 5 of the p53 gene in an extended cancer family. Law JC, Strong LC, Chidambaram A, Ferrell RE Cancer Res Dec. 1, 1991
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. Felix CA, Nau MM, Takahashi T, Mitsudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, et al. J Clin Invest Jan. 1, 1992
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, et al. N Engl J Med May 14, 1992
A novel mutation in the p53 gene in a Burkitt's lymphoma cell line. Bhatia K, Gutierrez MI, Magrath IT Hum Mol Genet June 1, 1992
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT, Colburn NH Proc Natl Acad Sci U S A July 15, 1992
Frequent p53 mutations in head and neck cancer. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G Cancer Res Nov. 1, 1992
Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. Crook T, Vousden KH EMBO J Nov. 1, 1992
p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Duthu A, Debuire B, Romano J, Ehrhart JC, Fiscella M, May E, Appella E, May P Oncogene Nov. 1, 1992
The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H, Tsuchida N Int J Cancer Dec. 2, 1992
p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ Am J Pathol April 1, 1993
Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Allalunis-Turner MJ, Barron GM, Day RS 3rd, Dobler KD, Mirzayans R Radiat Res June 1, 1993
Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G Oncogene Aug. 1, 1993
The incidence of p53 mutations increases with progression of head and neck cancer. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM, Sidransky D Cancer Res Oct. 1, 1993
p53: at the crossroads of molecular carcinogenesis and risk assessment. Harris CC Science Dec. 24, 1993
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, et al. Cancer Res March 1, 1994
A temperature-sensitive mutant of human p53. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB EMBO J June 1, 1994
High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborn AM Science July 15, 1994
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Cho Y, Gorina S, Jeffrey PD, Pavletich NP Science July 15, 1994
Solution structure of the tetrameric minimum transforming domain of p53. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH Nat Struct Biol Dec. 1, 1994
Germline mutations in the TP53 gene. Eeles RA Cancer Surv Jan. 1, 1995
Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Frebourg T, Barbier N, Yan YX, Garber JE, Dreyfus M, Fraumeni J Jr, Li FP, Friend SH Am J Hum Genet March 1, 1995
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Jeffrey PD, Gorina S, Pavletich NP Science March 10, 1995
An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG J Med Genet Dec. 1, 1995
Database of mutations in the p53 and APC tumor suppressor genes designed to facilitate molecular epidemiological analyses. De Vries EM, Ricke DO, De Vries TN, Hartmann A, Blaszyk H, Liao D, Soussi T, Kovach JS, Sommer SS Hum Mutat Jan. 1, 1996
Molecular analysis of the TP53 gene in Barrett's adenocarcinoma. Audrezet MP, Robaszkiewicz M, Mercier B, Nousbaum JB, Hardy E, Bail JP, Volant A, Lozac'h P, Gouerou H, Ferec C Hum Mutat Jan. 1, 1996
The human tumour suppressor gene p53 is alternatively spliced in normal cells. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T Oncogene Jan. 15, 1996
Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Shaw P, Freeman J, Bovey R, Iggo R Oncogene Jan. 15, 1996
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP Science Nov. 8, 1996
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Gorina S, Pavletich NP Science Nov. 8, 1996
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J Hum Mutat Jan. 1, 1997
Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ, Halazonetis TD EMBO J Oct. 15, 1997
Drastic genetic instability of tumors and normal tissues in Turcot syndrome. Miyaki M, Nishio J, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Muraoka M, Nagato M, Chong JM, Koike M, Terada T, Kawahara Y, Fukutome A, Tomiyama J, Chuganji Y, Momoi M, Utsunomiya J Oncogene Dec. 4, 1997
Detection of p53 gene mutations in oral squamous cell carcinomas of a black African population sample. van Rensburg EJ, Engelbrecht S, van Heerden WF, Kotze MJ, Raubenheimer EJ Hum Mutat Jan. 1, 1998
A germline missense mutation R337C in exon 10 of the human p53 gene. Luca JW, Strong LC, Hansen MF Hum Mutat Jan. 1, 1998
Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in a Li-Fraumeni syndrome family. Guran S, Tunca Y, Imirzalioglu N Cancer Genet Cytogenet Sept. 1, 1999
p53 and human cancer: the first ten thousand mutations. Hainaut P, Hollstein M Adv Cancer Res Jan. 1, 2000
p53 is involved in the p120E4F-mediated growth arrest. Sandy P, Gostissa M, Fogal V, Cecco LD, Szalay K, Rooney RJ, Schneider C, Del Sal G Oncogene Feb. 13, 2000
Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. Abraham J, Kelly J, Thibault P, Benchimol S J Mol Biol Feb. 28, 2000
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM J Biol Chem March 24, 2000
The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Lopez-Borges S, Lazo PA Oncogene July 27, 2000
Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. Anderson CW, Allalunis-Turner MJ Radiat Res Oct. 1, 2000
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H Mol Cell Jan. 1, 2001
Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. Chang NS, Pratt N, Heath J, Schultz L, Sleve D, Carey GB, Zevotek N J Biol Chem Jan. 2, 2001
p53 amino acids 339-346 represent the minimal p53 repression domain. Hong TM, Chen JJ, Peck K, Yang PC, Wu CW J Biol Chem Feb. 12, 2001
SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. Rodriguez MS, Dargemont C, Hay RT J Biol Chem April 20, 2001
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R Proc Natl Acad Sci U S A July 31, 2001
Zinc binding and redox control of p53 structure and function. Hainaut P, Mann K Antioxid Redox Signal Aug. 1, 2001
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA Cell Oct. 19, 2001
Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes. Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, Kito K, Ueda N, Shigemoto K, Hitsumoto Y, Nikawa J, Enomoto Y J Biol Chem Nov. 23, 2001
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML Nat Cell Biol Feb. 1, 2002
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S Nat Cell Biol Feb. 1, 2002
Differential effect of ik3-1/cables on p53- and p73-induced cell death. Tsuji K, Mizumoto K, Yamochi T, Nishimoto I, Matsuoka M J Biol Chem Feb. 25, 2002
Investigations on a clinically and functionally unusual and novel germline p53 mutation. Rutherford J, Chu CE, Duddy PM, Charlton RS, Chumas P, Taylor GR, Lu X, Barnes DM, Camplejohn RS Br J Cancer May 20, 2002
Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo. Kim EJ, Park JS, Um SJ J Biol Chem Aug. 1, 2002
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE, Shi Y Cell Dec. 27, 2002
Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A, Wakeham A, Tuan J, Saris C, Elliott G, Ma W, Benchimol S, Lowe SW, Mak TW, Thukral SK Proc Natl Acad Sci U S A April 1, 2003
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, Harris CC Cancer Res May 15, 2003
Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305. Wang YH, Tsay YG, Tan BC, Lo WY, Lee SC J Biol Chem July 11, 2003
Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. O'Keefe K, Li H, Zhang Y Mol Cell Biol Sept. 1, 2003
TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S, Malissen B, Dagorn JC, Iovanna JL, Dusetti NJ J Biol Chem Sept. 26, 2003
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL Proc Natl Acad Sci U S A Dec. 23, 2003
Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Li HH, Li AG, Sheppard HM, Liu X Mol Cell March 26, 2004
Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. An W, Kim J, Roeder RG Cell June 11, 2004
Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. Hasan MK, Yaguchi T, Minoda Y, Hirano T, Taira K, Wadhwa R, Kaul SC Biochem J June 15, 2004
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J Genome Res Oct. 1, 2004
Regulation of p53 activity through lysine methylation. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D Nature Nov. 18, 2004
Global phosphoproteome of HT-29 human colon adenocarcinoma cells. Kim JE, Tannenbaum SR, White FM J Proteome Res Jan. 1, 2005
Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. Jalota A, Singh K, Pavithra L, Kaul-Ghanekar R, Jameel S, Chattopadhyay S J Biol Chem April 22, 2005
WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q J Biol Chem Dec. 1, 2005
Structural basis for the methylation site specificity of SET7/9. Couture JF, Collazo E, Hauk G, Trievel RC Nat Struct Mol Biol Jan. 1, 2006
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. Hu M, Gu L, Li M, Jeffrey PD, Gu W, Shi Y PLoS Biol Jan. 1, 2006
Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. Gu YM, Jin YH, Choi JK, Baek KH, Yeo CY, Lee KY FEBS Lett Feb. 9, 2006
Molecular recognition of p53 and MDM2 by USP7/HAUSP. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH, Frappier L Nat Struct Mol Biol March 1, 2006
The consensus coding sequences of human breast and colorectal cancers. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE Science Oct. 13, 2006
Repression of p53 activity by Smyd2-mediated methylation. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL Nature Nov. 1, 2006
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Chanock SJ, Burdett L, Yeager M, Llaca V, Langerod A, Presswalla S, Kaaresen R, Strausberg RL, Gerhard DS, Kristensen V, Perou CM, Borresen-Dale AL Breast Cancer Res Jan. 1, 2007
Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Molina H, Horn DM, Tang N, Mathivanan S, Pandey A Proc Natl Acad Sci U S A Jan. 13, 2007
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T EMBO J Feb. 10, 2007
A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. Li HH, Cai X, Shouse GP, Piluso LG, Liu X EMBO J Feb. 24, 2007
The notch regulator MAML1 interacts with p53 and functions as a coactivator. Zhao Y, Katzman RB, Delmolino LM, Bhat I, Zhang Y, Gurumurthy CB, Germaniuk-Kurowska A, Reddi HV, Solomon A, Zeng MS, Kung A, Ma H, Gao Q, Dimri G, Stanculescu A, Miele L, Wu L, Griffin JD, Wazer DE, Band H, Band V J Biol Chem April 20, 2007
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ Science May 25, 2007
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M Hum Mutat June 1, 2007
p53 is regulated by the lysine demethylase LSD1. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL Nature Sept. 6, 2007
SVH-B interacts directly with p53 and suppresses the transcriptional activity of p53. Zhou X, Yang G, Huang R, Chen X, Hu G FEBS Lett Oct. 16, 2007
Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. Arai S, Matsushita A, Du K, Yagi K, Okazaki Y, Kurokawa R FEBS Lett Dec. 11, 2007
Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Shouse GP, Cai X, Liu X Mol Cell Biol Feb. 1, 2008
Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S Anal Chem June 1, 2009
JFK, a Kelch domain-containing F-box protein, links the SCF complex to p53 regulation. Sun L, Shi L, Li W, Yu W, Liang J, Zhang H, Yang X, Wang Y, Li R, Yao X, Yi X, Shang Y Proc Natl Acad Sci U S A June 23, 2009
Large-scale proteomics analysis of the human kinome. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, Mann M, Daub H Mol Cell Proteomics July 1, 2009
Plk1-mediated phosphorylation of Topors regulates p53 stability. Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, Liu X J Biol Chem July 10, 2009
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, Ha NC, Lane DP, Song J EMBO J July 22, 2009
Lysine acetylation targets protein complexes and co-regulates major cellular functions. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M Science Aug. 14, 2009
USP10 regulates p53 localization and stability by deubiquitinating p53. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z Cell Jan. 5, 2010
RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage. Fu X, Yucer N, Liu S, Li M, Yi P, Mu JJ, Yang T, Chu J, Jung SY, O'Malley BW, Gu W, Qin J, Wang Y Proc Natl Acad Sci U S A March 9, 2010

Last modification of this entry: June 19, 2013.

Add your own comment!

There is no comment yet.
Welcome stranger! Click here to login or here to register.
Valid HTML 4.01! This site is Emacs powered. Made with Django.